CA3195264A1 - Crystal forms of glp-1r agonists and uses thereof - Google Patents
Crystal forms of glp-1r agonists and uses thereofInfo
- Publication number
- CA3195264A1 CA3195264A1 CA3195264A CA3195264A CA3195264A1 CA 3195264 A1 CA3195264 A1 CA 3195264A1 CA 3195264 A CA3195264 A CA 3195264A CA 3195264 A CA3195264 A CA 3195264A CA 3195264 A1 CA3195264 A1 CA 3195264A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- compound
- crystalline form
- crystalline
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020120814 | 2020-10-14 | ||
| CNPCT/CN2020/120814 | 2020-10-14 | ||
| PCT/CN2021/123387 WO2022078352A1 (en) | 2020-10-14 | 2021-10-13 | Crystal forms of glp-1r agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3195264A1 true CA3195264A1 (en) | 2022-04-21 |
Family
ID=78401981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3195264A Pending CA3195264A1 (en) | 2020-10-14 | 2021-10-13 | Crystal forms of glp-1r agonists and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230382899A1 (enExample) |
| EP (1) | EP4228753B1 (enExample) |
| JP (1) | JP7769695B2 (enExample) |
| CN (1) | CN116710446B (enExample) |
| AU (1) | AU2021359493A1 (enExample) |
| CA (1) | CA3195264A1 (enExample) |
| ES (1) | ES3041328T3 (enExample) |
| TW (1) | TW202227421A (enExample) |
| WO (1) | WO2022078352A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761395B (zh) * | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| WO2023049518A1 (en) | 2021-09-27 | 2023-03-30 | Terns Pharmaceuticals, Inc. | Benzimidazole carboxylic acids as glp-1r agonists |
| WO2023076237A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| PE20250741A1 (es) | 2022-02-23 | 2025-03-13 | Terns Pharmaceuticals Inc | Compuestos como agonistas de glp-1r |
| CN117362282A (zh) * | 2022-07-07 | 2024-01-09 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| IL318410A (en) * | 2022-07-18 | 2025-03-01 | Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd | Polymorphic form of GLP-1R agonist, method of preparation thereof and use thereof |
| EP4568664A1 (en) | 2023-04-07 | 2025-06-18 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| TW202521533A (zh) | 2023-09-14 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP2262364B1 (en) | 2008-03-07 | 2016-03-02 | vTv Therapeutics LLC | Oxadiazoanthracene compounds for the treatment of diabetes |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| MA56480B1 (fr) | 2016-12-16 | 2022-12-30 | Pfizer | Agonistes du récepteur glp-1 et leurs utilisations |
| EP3806855B1 (en) | 2018-06-15 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CU20210042A7 (es) * | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| CR20210562A (es) * | 2019-04-12 | 2022-02-18 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r y usos de los mismos |
| US10954221B2 (en) * | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
-
2021
- 2021-10-13 AU AU2021359493A patent/AU2021359493A1/en active Pending
- 2021-10-13 WO PCT/CN2021/123387 patent/WO2022078352A1/en not_active Ceased
- 2021-10-13 EP EP21798552.2A patent/EP4228753B1/en active Active
- 2021-10-13 JP JP2023523059A patent/JP7769695B2/ja active Active
- 2021-10-13 US US18/031,380 patent/US20230382899A1/en active Pending
- 2021-10-13 CN CN202180082321.9A patent/CN116710446B/zh active Active
- 2021-10-13 ES ES21798552T patent/ES3041328T3/es active Active
- 2021-10-13 TW TW110138006A patent/TW202227421A/zh unknown
- 2021-10-13 CA CA3195264A patent/CA3195264A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7769695B2 (ja) | 2025-11-13 |
| TW202227421A (zh) | 2022-07-16 |
| US20230382899A1 (en) | 2023-11-30 |
| JP2023546125A (ja) | 2023-11-01 |
| EP4228753B1 (en) | 2025-07-30 |
| AU2021359493A9 (en) | 2025-01-09 |
| WO2022078352A1 (en) | 2022-04-21 |
| ES3041328T3 (en) | 2025-11-11 |
| EP4228753A1 (en) | 2023-08-23 |
| CN116710446A (zh) | 2023-09-05 |
| CN116710446B (zh) | 2024-10-18 |
| AU2021359493A1 (en) | 2023-06-15 |
| EP4228753C0 (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4157832B1 (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| EP4228753B1 (en) | Crystal forms of glp-1r agonists and uses thereof | |
| CN112533674B (zh) | Glp-1受体激动剂及其用途 | |
| TWI809334B (zh) | ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式 | |
| RU2740135C1 (ru) | Агонисты рецептора glp-1 и их применение | |
| TW202214622A (zh) | Ｇｌｐ－１ｒ促效劑及其用途 | |
| US20250129057A1 (en) | Solid Forms of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt | |
| WO2023164050A1 (en) | Compounds as glp-1r agonists | |
| HK40089377B (en) | Crystal forms of glp-1r agonists and uses thereof | |
| HK40089377A (en) | Crystal forms of glp-1r agonists and uses thereof | |
| HK40087545B (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| HK40087545A (en) | Salt and crystal forms of glp-1r agonists and uses thereof |